Search

Your search keyword '"Pérez Pérez, Antonio"' showing total 527 results
Start Over Author "Pérez Pérez, Antonio"
527 results on '"Pérez Pérez, Antonio"'

3. Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?

Author

Arrobas Velilla Teresa, Guijarro Carlos, Ruiz Raquel Campuzano, Piñero Manuel Rodríguez, Valderrama Marcos José Francisco, Pérez Pérez Antonio, Botana López Antonio M., López Ana Morais, García Donaire José Antonio, Obaya Juan Carlos, Castilla-Guerra Luis, Carratalá Vicente Pallares, Cabello Isabel Egocheaga, Lazo Mercedes Salgueira, Castellanos Rodrigo María Mar, Mostaza Prieto José María, Gómez Doblas Juan José, and Buño Soto Antonio

Subjects
apolipoprotein b, biochemistry, cardiovascular diseases, cholesterol, consensus, lipoprotein (a), Medical technology, R855-855.5
Abstract

Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.

Published
2023
Full Text
View/download PDF

4. Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles: ¿Qué parámetros debe incluir un perfil lipídico básico?

Author

Arrobas Velilla Teresa, Guijarro Carlos, Campuzano Ruiz Raquel, Rodríguez Piñero Manuel, Valderrama Marcos José Francisco, Pérez Pérez Antonio, Botana López Manuel Antonio, Morais López Ana, García Donaire José Antonio, Obaya Juan Carlos, Castilla Guerra Luis, Pallares Carratalá Vicente, Egocheaga Cabello Isabel, Salgueira Lazo Mercedes, Castellanos Rodrigo María Mar, Mostaza Prieto José María, Gómez Doblas Juan José, and Buño Soto Antonio

Subjects
consenso, panel de lípidos, enfermedades cardiovasculares, bioquímica, colesterol, lípidos, triglicéridos, lipoproteína (a), apolipoproteína b, Medical technology, R855-855.5
Abstract

Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio.

Published
2023
Full Text
View/download PDF

5. Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles: ¿Qué parámetros debe incluir un perfil lipídico básico?

Author

Arrobas Velilla, Teresa, Guijarro, Carlos, Campuzano Ruiz, Raquel, Rodríguez Piñero, Manuel, Valderrama Marcos, José Francisco, Pérez Pérez, Antonio, Botana López, Manuel Antonio, Morais López, Ana, García Donaire, José Antonio, Obaya, Juan Carlos, Castilla Guerra, Luis, Pallares Carratalá, Vicente, Egocheaga Cabello, Isabel, Salgueira Lazo, Mercedes, Castellanos Rodrigo, María Mar, Mostaza Prieto, José María, Gómez Doblas, Juan José, and Buño Soto, Antonio

Published
2023
Full Text
View/download PDF

6. Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: What parameters should a basic lipid profile include?

Author

Arrobas Velilla, Teresa, Guijarro, Carlos, Campuzano Ruiz, Raquel, Rodríguez Piñero, Manuel, Valderrama Marcos, José Francisco, Pérez Pérez, Antonio, Botana López, Manuel Antonio, Morais López, Ana, García Donaire, José Antonio, Carlos Obaya, Juan, Castilla Guerra, Luis, Pallares Carratalá, Vicente, Egocheaga Cabello, Isabel, Salgueira Lazo, Mercedes, Castellanos Rodrigo, María Mar, Mostaza Prieto, José María, Gómez Doblas, Juan José, and Buño Soto, Antonio

Published
2023
Full Text
View/download PDF

7. Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention

Author

Brotons, Carlos, Camafort, Miguel, Castellanos, María del Mar, Clarà, Albert, Cortés, Olga, Diaz Rodríguez, Ángel, Elosua, Roberto, Gorostidi, Manuel, Hernández, Antonio M., Herranz, María, Justo, Soledad, Lahoz, Carlos, Niño, Pilar, Pallarés-Carratalá, Vicente, Pedro-Botet, Juan, Pérez Pérez, Antonio, Royo-Bordonada, Miguel Ángel, Santamaría, Rafael, Tresserras, Ricard, Zamora, Alberto, Zuza, Inés, and Armario, Pedro

Published
2023
Full Text
View/download PDF

8. Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021

Author

Brotons, Carlos, Camafort, Miguel, Castellanos, María del Mar, Clarà, Albert, Cortés, Olga, Diaz Rodríguez, Ángel, Elosua, Roberto, Gorostidi, Manuel, Hernández, Antonio M., Herranz, María, Justo, Soledad, Lahoz, Carlos, Niño, Pilar, Pallarés-Carratalá, Vicente, Pedro-Botet, Juan, Pérez Pérez, Antonio, Royo-Bordonada, Miguel Ángel, Santamaría, Rafael, Tresserras, Ricard, Zamora, Alberto, Zuza, Inés, and Armario, Pedro

Published
2023
Full Text
View/download PDF

10. Consensus document for lipid profile determination and reporting in Spanish clinical laboratories: What parameters should a basic lipid profile include?

Author

Arrobas Velilla, Teresa, Guijarro, Carlos, Campuzano Ruiz, Raquel, Rodríguez Piñero, Manuel, Valderrama Marcos, José Francisco, Pérez Pérez, Antonio, Botana López, Manuel Antonio, Morais López, Ana, García Donaire, José Antonio, Obaya, Juan Carlos, Castilla Guerra, Luis, Pallares Carratalá, Vicente, Egocheaga Cabello, Isabel, Salgueira Lazo, Mercedes, Castellanos Rodrigo, María Mar, Mostaza Prieto, José María, Gómez Doblas, Juan José, and Buño Soto, Antonio

Published
2023
Full Text
View/download PDF

11. Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021

Author

Brotons, Carlos, Camafort, Miguel, Castellanos, María del Mar, Clarà, Albert, Cortés, Olga, Diaz Rodriguez, Angel, Elosua, Roberto, Gorostidi, Manuel, Hernández, Antonio M., Herranz, María, Justo, Soledad, Lahoz, Carlos, Niño, Pilar, Pallarés-Carratalá, Vicente, Pedro-Botet, Juan, Pérez Pérez, Antonio, Royo-Bordonada, Miguel Angel, Santamaria, Rafael, Tresserras, Ricard, Zamora, Alberto, Zuza, Inés, and Armario, Pedro

Published
2022
Full Text
View/download PDF

12. Comprehensive management of risk factors in peripheral vascular disease. Expert consensus

Author

Aicart Bort, Mª Dolores, Almagro Múgica, Fátima, Arrarte Esteban, Vicente Ignacio, Ayala Vigueras, Isabel, Barquilla García, Alfonso, Bellido Castañeda, Virginia, Berenguel Senén, Alejandro, Blanco Echevarría, Agustín, Botana López, Manuel Antonio, Brea Hernando, Ángel, Brito Banfiel, Miguel, Calsina Juscafresa, Laura, Cánovas Molina, María Gloria, Carbayo Herencia, Julio Antonio, Carrasco Carrasco, Eduardo, Carro, Amelia, Casañas Martínez, Marta, Castilla-Guerra, Luis, Cepeda Rodrigo, José María, Cinza-Sanjurjo, Sergio, Clarà, Albert, Comas Samper, José Manuel, Cordero, Alberto, Cosin Sales, Juan, de Juan Bagudá, Javier, de la Fuente, Natalia, Delgado, Elías, Doiz Artázcoz, Esther, Durán Martínez, María, Escalada, Javier, Escobar Cervantes, Carlos, Escribano Pardo, Daniel, Estallo Laliena, Luis, Félix Redondo, Francisco Javier, Fernández Pardo, Jacinto, Rodriguez-Lacin, Jose María Fernández, Ferrer García, Juan Carlos, Frías Vargas, Manuel, Galarza Tapia, Andrés, García León, Andrés, García Lerín, Aurora, García-Martín, Lisardo, Gargallo Fernández, Manuel, Gil, Inés Gil, Girbés Borrás, Juan, Guerra Requena, Mercedes, Guijarro Herraiz, Carlos, Hernández Martínez, Antonio Miguel, Hevia, Sergio, Ibarretxe Gerediaga, Daiana, Iborra Ortega, Elena, Jansen Chaparro, Sergio, Jarauta Simón, Estíbaliz, Jericó Alba, Carlos, Jiménez Muñoz, Beatriz, Lahoz, Carlos, Leiva Hernando, Luis, León Mazorra, Magdalena, López Valverde, María Eugenia, Lorente Calvo, Rosario, Martín Cañuelo, Jorge Jesús, Martínez Hervas, Sergio, Martínez López, María Ángeles, Masmiquel, Luis, Matía Cubillo, Ángel Carlos, Medina Falcón, Agustín, Merino Lanza, Esther, Morales-Pérez, Francisco M., Morata Barrado, Pilar Caridad, Moreno-Pérez, Óscar, Morillas Bueno, Miren, Mosquera Lozano, Jose Daniel, Muñiz Grijalvo, Ovidio, Muñoz Rivas, Núria, Navas de Solís, María Soledad, Obaya Rebollar, Juan Carlos, Ortega, Emilio, Pallarés-Carratalá, Vicente, Párraga Martínez, Ignacio, Pascual Fuster, Vicente, Peinado Adiego, Carmen, Pereira López, Eva María, Pérez Lázaro, M. Antonia, Pérez Pérez, Antonio, Pinés Corrales, Pedro J., Polo García, Jose, Prieto Díaz, Miguel Ángel, Quindimil Vázquez, José Antonio, Rama Martínez, Teresa, Reyes García, Rebeca, Ripoll Vera, Tomás, Rodilla Sala, Enrique, Rodríguez Piñero, Manuel, de Buruaga, Víctor Rodríguez Sáenz, Ruiz García, Antonio, Ruiz Ortiz, Martín, Ruiz Palomar, José Manuel, Saltijeral Cerezo, Adriana, Álvarez, Julio Sánchez, Ortiga, Ruth Sánchez, Sánchez-Hernández, Rosa María, Santos Altozano, Carlos, Seoane Vicente, Maria, Suárez Tembra, Manuel, Tejera Pérez, Cristina, Toledo Frías, Pablo Antonio, Turégano Yedro, Miguel, Valdivielso, Pedro, Valls-Roca, Francisco, de Ceniga, Melina Vega, Velasco Valdazo, Elisa, Vidal-Pérez, Rafael, Zamora Cervantes, Alberto, Barrios, V., Beato, P., Brotons, C., Campuzano, R., Merino-Torres, J.F., Mostaza, J.M., Plana, N., Rubio, J.A., and Comellas, M.

Published
2022
Full Text
View/download PDF

15. Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines

Author

Armario, Pedro, Brotons, Carlos, Elosua, Roberto, Alonso de Leciñana, Maria, Castro, Almudena, Clarà, Albert, Cortés, Olga, Díaz Rodriguez, Ángel, Herranz, María, Justo, Soledad, Lahoz, Carlos, Pedro-Botet, Juan, Pérez Pérez, Antonio, Santamaria, Rafael, Tresserras, Ricard, Aznar Lain, Susana, and Royo-Bordonada, Miguel Ángel

Published
2021
Full Text
View/download PDF

16. Comentario del CEIPV a la actualización de las Guías Europeas de Prevención Vascular en la Práctica Clínica

Author

Armario, Pedro, Brotons, Carlos, Elosua, Roberto, Alonso de Leciñana, Maria, Castro, Almudena, Clarà, Albert, Cortés, Olga, Díaz Rodriguez, Ángel, Herranz, María, Justo, Soledad, Lahoz, Carlos, Pedro-Botet, Juan, Pérez Pérez, Antonio, Santamaria, Rafael, Tresserras, Ricard, Aznar Lain, Susana, and Royo-Bordonada, Miguel Ángel

Published
2021
Full Text
View/download PDF

17. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes

Author

Junta de Andalucía, Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Vilariño-García, Teresa, Polonio-González, María L., Pérez-Pérez, Antonio, Ribalta, Josep, Arrieta, Francisco, Aguilar, Manuel, Obaya, Juan C., Gimeno-Orna, José A., Iglesias, Pedro, Navarro, Jorge, Durán, Santiago, Pedro-Botet, Juan, Sánchez-Margalet, Víctor, Junta de Andalucía, Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Vilariño-García, Teresa, Polonio-González, María L., Pérez-Pérez, Antonio, Ribalta, Josep, Arrieta, Francisco, Aguilar, Manuel, Obaya, Juan C., Gimeno-Orna, José A., Iglesias, Pedro, Navarro, Jorge, Durán, Santiago, Pedro-Botet, Juan, and Sánchez-Margalet, Víctor

Abstract

Diabetes mellitus (DM) is a highly prevalent disease worldwide, estimated to affect 1 in every 11 adults; among them, 90–95% of cases are type 2 diabetes mellitus. This is partly attributed to the surge in the prevalence of obesity, which has reached epidemic proportions since 2008. In these patients, cardiovascular (CV) risk stands as the primary cause of morbidity and mortality, placing a substantial burden on healthcare systems due to the potential for macrovascular and microvascular complications. In this context, leptin, an adipocyte-derived hormone, plays a fundamental role. This hormone is essential for regulating the cellular metabolism and energy balance, controlling inflammatory responses, and maintaining CV system homeostasis. Thus, leptin resistance not only contributes to weight gain but may also lead to increased cardiac inflammation, greater fibrosis, hypertension, and impairment of the cardiac metabolism. Understanding the relationship between leptin resistance and CV risk in obese individuals with type 2 DM (T2DM) could improve the management and prevention of this complication. Therefore, in this narrative review, we will discuss the evidence linking leptin with the presence, severity, and/or prognosis of obesity and T2DM regarding CV disease, aiming to shed light on the potential implications for better management and preventive strategies.

Published
2024

18. Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes.

Author

Guardiola, Montse, Rehues, Pere, Amigó, Núria, Arrieta, Francisco, Botana, Manuel, Gimeno‐Orna, José A., Girona, Josefa, Martínez‐Montoro, José Ignacio, Ortega, Emilio, Pérez‐Pérez, Antonio, Sánchez‐Margalet, Víctor, Pedro‐Botet, Juan, Ribalta, Josep, Aguilar Diosdado, Manuel, Arrieta, Francisco J., Becerra Fernández, Antonio, Botana López, Manuel Antonio, Campos Pastor, María del Mar, Durán García, Santiago, and Fornos Pérez, José Antonio

Subjects
TYPE 2 diabetes, DYSLIPIDEMIA, CARDIOVASCULAR diseases risk factors, LDL cholesterol, HDL cholesterol, NUCLEAR magnetic resonance
Abstract

The burden of cardiovascular disease is particularly high among individuals with diabetes, even when LDL cholesterol is normal or within the therapeutic target. Despite this, cholesterol accumulates in their arteries, in part, due to persistent atherogenic dyslipidaemia characterized by elevated triglycerides, remnant cholesterol, smaller LDL particles and reduced HDL cholesterol. The causal link between dyslipidaemia and atherosclerosis in T2DM is complex, and our contention is that a deeper understanding of lipoprotein composition and functionality, the vehicle that delivers cholesterol to the artery, will provide insight for improving our understanding of the hidden cardiovascular risk of diabetes. This narrative review covers three levels of complexity in lipoprotein characterization: 1—the information provided by routine clinical biochemistry, 2—advanced nuclear magnetic resonance (NMR)‐based lipoprotein profiling and 3—the identification of minor components or physical properties of lipoproteins that can help explain arterial accumulation in individuals with normal LDLc levels, which is typically the case in individuals with T2DM. This document highlights the importance of incorporating these three layers of lipoprotein‐related information into population‐based studies on ASCVD in T2DM. Such an attempt should inevitably run in parallel with biotechnological solutions that allow large‐scale determination of these sets of methodologically diverse parameters. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Influence of the Surface Topography of Titanium Dental Implants on the Behavior of Human Amniotic Stem Cells.

Author

Riedel, Rodrigo, Pérez-Amodio, Soledad, Cabo-Zabala, Laura, Velasco-Ortega, Eugenio, Maymó, Julieta, Gil, Javier, Monsalve-Guil, Loreto, Ortiz-Garcia, Iván, Pérez-Pérez, Antonio, Sánchez-Margalet, Victor, and Jiménez-Guerra, Alvaro

Subjects
HUMAN stem cells, DENTAL implants, SURFACE topography, TITANIUM, SURFACE energy
Abstract

The dental implant surface plays a crucial role in osseointegration. The topography and physicochemical properties will affect the cellular functions. In this research, four distinct titanium surfaces have been studied: machined acting (MACH), acid etched (AE), grit blasting (GBLAST), and a combination of grit blasting and subsequent acid etching (GBLAST + AE). Human amniotic mesenchymal (hAMSCs) and epithelial stem cells (hAECs) isolated from the amniotic membrane have attractive stem-cell properties. They were cultured on titanium surfaces to analyze their impact on biological behavior. The surface roughness, microhardness, wettability, and surface energy were analyzed using interferometric microscopy, Vickers indentation, and drop-sessile techniques. The GBLAST and GBLAST + AE surfaces showed higher roughness, reduced hydrophilicity, and lower surface energy with significant differences. Increased microhardness values for GBLAST and GBLAST + AE implants were attributed to surface compression. Cell viability was higher for hAMSCs, particularly on GBLAST and GBLAST + AE surfaces. Alkaline phosphatase activity enhanced in hAMSCs cultured on GBLAST and GBLAST + AE surfaces, while hAECs showed no mineralization signals. Osteogenic gene expression was upregulated in hAMSCs on GBLAST surfaces. Moreover, α2 and β1 integrin expression enhanced in hAMSCs, suggesting a surface−integrin interaction. Consequently, hAMSCs would tend toward osteoblastic differentiation on grit-blasted surfaces conducive to osseointegration, a phenomenon not observed in hAECs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Tissue‐specific early and late activated lymphocytes immunophenotype in chronic rhinosinusitis with nasal polyps.

Author

López‐Enríquez, Soledad, Porras‐González, Cristina, Moreno‐Luna, Ramón, Palomares, Francisca, Muñoz‐Bravo, José Luis, Alba, Gonzalo, Santa‐María, Consuelo, Maza‐Solano, Juan, Martín‐Jiménez, Daniel Iván, Pérez‐Pérez, Antonio, Moreno‐Luna, Rafael, Sánchez‐Margalet, Víctor, and Sánchez‐Gómez, Serafín

Published
2024
Full Text
View/download PDF

21. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes

Author

Vilariño-García, Teresa, primary, Polonio-González, María, additional, Pérez-Pérez, Antonio, additional, Ribalta, Josep, additional, Arrieta, Francisco, additional, Aguilar, Manuel, additional, Obaya, Juan, additional, Gimeno-Orna, José, additional, Iglesias, Pedro, additional, Navarro, Jorge, additional, Durán, Santiago, additional, Pedro-Botet, Juan, additional, and Sánchez-Margalet, Víctor, additional

Published
2024
Full Text
View/download PDF

24. Study of the diagnostic efficiency of anti-ZnT8 autoantibodies for type 1 diabetes in pediatric patients.

Author

Fuentes-Cantero, Sandra, González-Rodríguez, Concepción, Rodríguez-Chacón, Carmen, Galvan-Toribio, Raquel, Hermosín-Escudero, Joaquín, Pérez-Pérez, Antonio, and León-Justel, Antonio

Subjects
TYPE 1 diabetes, QUALITATIVE research, DATA analysis, AUTOANTIBODIES, RESEARCH evaluation, GLYCEMIC control, ENZYME-linked immunosorbent assay, KRUSKAL-Wallis Test, RETROSPECTIVE studies, DESCRIPTIVE statistics, QUANTITATIVE research, CHI-squared test, MANN Whitney U Test, PEDIATRICS, ANTIGENS, GLUTAMIC acid, C-peptide, MEDICAL records, ACQUISITION of data, STATISTICS, CONFIDENCE intervals, DATA analysis software, COMPARATIVE studies, SENSITIVITY & specificity (Statistics), EVALUATION, CHILDREN
Abstract

Objective Zinc transporter 8 autoantibodies (ZNt8A) are 1 of the 4 main autoantibodies used for the diagnosis of type 1 diabetes (T1D), with glutamic acid decarboxylase autoantibodies (GADA), islet antigen-2 autoantibodies (IA-2A), and insulin autoantibodies (IAA). The objective of this study is to evaluate the diagnostic efficiency of these autoantibodies for the diagnosis of T1D in pediatric patients. Methods A retrospective analysis of patients under 16 years of age with suspected T1D was made between June 2020 and January 2021. A total of 80 patients were included in the study, with 1 sample per patient. Subjects were classified according to diagnosis. Results Of the subjects included in the study, 50 developed T1D. The diagnostic efficacy was IA-2A (cutoff ≥ 28 U/L) sensitivity 0.26 (95% CI: 0.14-0.38) and specificity 0.97 (95% CI: 0.79-1.0); GADA (cutoff ≥ 17 U/mL) sensitivity 0.40 (95% CI: 0.26-0.54) and specificity 0.87 (95% CI: 0.75-0.99); ZnT8A (cut off ≥ 15 U/L) sensitivity 0.62 (95% CI: 0.49-0.75) and specificity 0.97 (95% CI: 0.90-1.0). ZnT8A obtained the most significantly global diagnostic accuracy (0.75), and GADA with ZnT8A showed the highest correlation. Conclusion The results obtained indicate a higher efficiency of anti-ZnT8 autoantibodies for the diagnosis of T1D in pediatric patients. Clinical efficiency of diabetic autoantibodies is method and assay dependent and influences combined diagnostic strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization

Author

Jiménez-Cortegana, Carlos, primary, Salamanca, Elena, additional, Palazón-Carrión, Natalia, additional, Sánchez-Jiménez, Flora, additional, Pérez-Pérez, Antonio, additional, Vilariño-García, Teresa, additional, Fuentes, Sandra, additional, Martín, Salomón, additional, Jiménez, Marta, additional, Galván, Raquel, additional, Rodríguez-Chacón, Carmen, additional, Sánchez-Mora, Catalina, additional, Moreno-Mellado, Elisa, additional, Gutiérrez-Gutiérrez, Belén, additional, Álvarez, Nerissa, additional, Sosa, Alberto, additional, Garnacho-Montero, José, additional, de la Cruz-Merino, Luis, additional, Rodríguez-Baño, Jesús, additional, and Sánchez-Margalet, Víctor, additional

Published
2023
Full Text
View/download PDF

27. Leptin and Gestational Diabetes Mellitus

Author

Guadix, Pilar, primary, Pérez-Pérez, Antonio, additional, Vilariño-García, Teresa, additional, L. Dueñas, José, additional, Maymó, Julieta, additional, Varone, Cecilia, additional, and Sánchez-Margalet, Víctor, additional

Published
2020
Full Text
View/download PDF

28. Aquaporins and placenta

Author

Pérez-Pérez, Antonio, primary, Vilariño-García, Teresa, additional, Dietrich, Valeria, additional, Guadix, Pilar, additional, Dueñas, José L., additional, Varone, Cecilia L., additional, Damiano, Alicia E., additional, and Sánchez-Margalet, Víctor, additional

Published
2020
Full Text
View/download PDF

30. Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles

Author

Arrobas Velilla, Teresa, primary, Guijarro, Carlos, additional, Campuzano Ruiz, Raquel, additional, Rodríguez Piñero, Manuel, additional, Valderrama Marcos, José Francisco, additional, Pérez Pérez, Antonio, additional, Botana López, Manuel Antonio, additional, Morais López, Ana, additional, García Donaire, José Antonio, additional, Obaya, Juan Carlos, additional, Castilla Guerra, Luis, additional, Pallares Carratalá, Vicente, additional, Egocheaga Cabello, Isabel, additional, Salgueira Lazo, Mercedes, additional, Castellanos Rodrigo, María Mar, additional, Mostaza Prieto, José María, additional, Gómez Doblas, Juan José, additional, and Buño Soto, Antonio, additional

Published
2023
Full Text
View/download PDF

33. Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles: ¿qué parámetros debe incluir un perfil lipídico básico?

Author

Arrobas-Velilla, Teresa, Guijarro, Carlos, Campuzano-Ruiz, Raquel, Rodríguez-Piñero, Manuel, Valderrama-Marcos, José Francisco, Pérez-Pérez, Antonio, Botana-López, Manuel Antonio, Morais-López, Ana, García-Donaire, José Antonio, Obaya-Rebollar, Juan Carlos, Castilla-Guerra, Luis, Pallarés-Carratalá, Vicente, Egocheaga Cabello, Isabel, Salgueira-Lazo, Mercedes, Castellanos, María del Mar, Mostaza, José María, Gómez-Doblas, Juan José, Buño-Soto, Antonio S., Arrobas-Velilla, Teresa, Guijarro, Carlos, Campuzano-Ruiz, Raquel, Rodríguez-Piñero, Manuel, Valderrama-Marcos, José Francisco, Pérez-Pérez, Antonio, Botana-López, Manuel Antonio, Morais-López, Ana, García-Donaire, José Antonio, Obaya-Rebollar, Juan Carlos, Castilla-Guerra, Luis, Pallarés-Carratalá, Vicente, Egocheaga Cabello, Isabel, Salgueira-Lazo, Mercedes, Castellanos, María del Mar, Mostaza, José María, Gómez-Doblas, Juan José, and Buño-Soto, Antonio S.

Abstract

[Resumen] Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio., [Abstract] Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.

Published
2023

34. Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization

Author

Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Jiménez Cortegana, Carlos, Salamanca, Elena, Palazón Carrión, Natalia, Sánchez Jiménez, Flora, Pérez Pérez, Antonio, Vilariño García, Teresa, Gutiérrez Gutiérrez, Belén, Garnacho Montero, José, Cruz Merino, Luis de la, Rodríguez-Baño, Jesús, Sánchez Margalet, Víctor, Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Jiménez Cortegana, Carlos, Salamanca, Elena, Palazón Carrión, Natalia, Sánchez Jiménez, Flora, Pérez Pérez, Antonio, Vilariño García, Teresa, Gutiérrez Gutiérrez, Belén, Garnacho Montero, José, Cruz Merino, Luis de la, Rodríguez-Baño, Jesús, and Sánchez Margalet, Víctor

Abstract

SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences in the severity, complications and outcomes of the COVID-19 are intriguing and, patients with similar baseline clinical conditions may have very different evolution. Myeloid-derived suppressor cells (MDSCs) have been previously found to be recruited by the SARS-CoV-2 infection and may be a marker of clinical evolution in these patients. We have studied 90 consecutive patients admitted in the hospital before the vaccination program started in the general population, to measure MDSCs and lymphocyte subpopulations at admission and one week after to assess the possible association with unfavorable outcomes (dead or Intensive Care Unit admission). We analyzed MDSCs and lymphocyte subpopulations by flow cytometry. In the 72 patients discharged from the hospital, there were significant decreases in the monocytic and total MDSC populations measured in peripheral blood after one week but, most importantly, the number of MDSCs (total and both monocytic and granulocytic subsets) were much higher in the 18 patients with unfavorable outcome. In conclusion, the number of circulating MDSCs may be a good marker of evolution in the follow-up of unvaccinated patients admitted in the hospital with the diagnosis of COVID-19.

Published
2023

35. Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization

Author

Junta de Andalucía, Jiménez-Cortegana, Carlos, Salamanca, Elena, Palazón-Carrión, Natalia, Sánchez-Jiménez, Flora, Pérez-Pérez, Antonio, Vilariño-García, Teresa, Fuentes, Sandra, Martín, Salomón, Jiménez, Marta, Galván, Raquel, Rodríguez-Chacón, Carmen, Sánchez-Mora, Catalina, Moreno-Mellado, Elisa, Gutiérrez-Gutiérrez, Belén, Álvarez, Nerissa, Sosa, Alberto, Garnacho-Montero, José, Cruz-Merino, Luis de la, Rodríguez-Baño, Jesús, Sánchez-Margalet, Víctor, Junta de Andalucía, Jiménez-Cortegana, Carlos, Salamanca, Elena, Palazón-Carrión, Natalia, Sánchez-Jiménez, Flora, Pérez-Pérez, Antonio, Vilariño-García, Teresa, Fuentes, Sandra, Martín, Salomón, Jiménez, Marta, Galván, Raquel, Rodríguez-Chacón, Carmen, Sánchez-Mora, Catalina, Moreno-Mellado, Elisa, Gutiérrez-Gutiérrez, Belén, Álvarez, Nerissa, Sosa, Alberto, Garnacho-Montero, José, Cruz-Merino, Luis de la, Rodríguez-Baño, Jesús, and Sánchez-Margalet, Víctor

Abstract

SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences in the severity, complications and outcomes of the COVID-19 are intriguing and, patients with similar baseline clinical conditions may have very different evolution. Myeloid-derived suppressor cells (MDSCs) have been previously found to be recruited by the SARS-CoV-2 infection and may be a marker of clinical evolution in these patients. We have studied 90 consecutive patients admitted in the hospital before the vaccination program started in the general population, to measure MDSCs and lymphocyte subpopulations at admission and one week after to assess the possible association with unfavorable outcomes (dead or Intensive Care Unit admission). We analyzed MDSCs and lymphocyte subpopulations by flow cytometry. In the 72 patients discharged from the hospital, there were significant decreases in the monocytic and total MDSC populations measured in peripheral blood after one week but, most importantly, the number of MDSCs (total and both monocytic and granulocytic subsets) were much higher in the 18 patients with unfavorable outcome. In conclusion, the number of circulating MDSCs may be a good marker of evolution in the follow-up of unvaccinated patients admitted in the hospital with the diagnosis of COVID-19.

Published
2023

36. The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

Author

Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Universidad de Sevilla. Departamento de Medicina, Navajas Hernández, Pilar, Pino Bellido, Pilar del, Lorenzo González, Laura, González Rodríguez, Concepción, Pérez Pérez, Antonio, Argüelles Arias, Federico, Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Universidad de Sevilla. Departamento de Medicina, Navajas Hernández, Pilar, Pino Bellido, Pilar del, Lorenzo González, Laura, González Rodríguez, Concepción, Pérez Pérez, Antonio, and Argüelles Arias, Federico

Abstract

Background: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) have been shadowed by the development of an ti-drug antibodies that reduce their effectiveness. The HLA DQA1*05 allele has been shown to increase the risk of im munogenicity to anti-TNF drugs by approximately two-fold. The negative impact of this allele has not been fully inves tigated for newer biotherapies. Objective: whether the presence of the HLA-DQA1*05 al lele is associated with a reduction of response to usteki numab and vedolizumab was investigated. Material and methods: the impact of HLA-DQA1*05 on dis ease activity in 93 patients with IBD, treated with ustekinum ab (n = 39) or vedolizumab (n = 54) was investigated in a ret rospective cohort study. Treatment response and remission was assessed at 6 and 12 months for ustekinumab, and up to 18 and 24 months for vedolizumab, using Harvey-Bradshaw index (Crohn’s disease) and Mayo score (ulcerative colitis). Results: the HLA-DQA1*05 allele was found in 35.9 % and 38.9 % of patients treated with ustekinumab and vedoli zumab, respectively. Clinical response was not affected by the presence of the HLA-DQA1*05 allele for both treat ment groups. Conclusions: in contrast to anti-TNF drugs, HLA-DQA1*05 presence does not correlate with the decreased response to ustekinumab or vedolizumab.

Published
2023

42. Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias. Divergencia entre las guías europea y estadounidense

Author

Lobos Bejarano, José María, Galve, Enrique, Royo-Bordonada, Miguel Ángel, Alegría Ezquerra, Eduardo, Armario, Pedro, Brotons Cuixart, Carlos, Camafort Babkowski, Miguel, Cordero Fort, Alberto, Maiques Galán, Antonio, Mantilla Morató, Teresa, Pérez Pérez, Antonio, Pedro-Botet, Juan, Villar Álvarez, Fernando, and González-Juanatey, José Ramón

Published
2015
Full Text
View/download PDF

45. Obesity and Risk for Lymphoma: Possible Role of Leptin

Author

Jiménez-Cortegana, Carlos, primary, Hontecillas-Prieto, Lourdes, additional, García-Domínguez, Daniel J., additional, Zapata, Fernando, additional, Palazón-Carrión, Natalia, additional, Sánchez-León, María L., additional, Tami, Malika, additional, Pérez-Pérez, Antonio, additional, Sánchez-Jiménez, Flora, additional, Vilariño-García, Teresa, additional, de la Cruz-Merino, Luis, additional, and Sánchez-Margalet, Víctor, additional

Published
2022
Full Text
View/download PDF

47. Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines

Author

Lobos Bejarano, José María, Galve, Enrique, Royo-Bordonada, Miguel Ángel, Alegría Ezquerra, Eduardo, Armario, Pedro, Brotons Cuixart, Carlos, Camafort Babkowski, Miguel, Cordero Fort, Alberto, Maiques Galán, Antonio, Mantilla Morató, Teresa, Pérez Pérez, Antonio, Pedro-Botet, Juan, Villar Álvarez, Fernando, and González-Juanatey, José Ramón

Published
2014
Full Text
View/download PDF

49. Expression of nutrient transporters in placentas affected by gestational diabetes: role of leptin.

Author

Guadix, Pilar, Corrales, Isabel, Vilariño-García, Teresa, Rodríguez-Chacón, Carmen, Sánchez-Jiménez, Flora, Jimeénez-Cortegana, Carlos, Dueñas, José L., Sánchez-Margalet, Víctor, and Pérez-Pérez, Antonio

Subjects
GESTATIONAL diabetes, FETAL death, LEPTIN receptors, LEPTIN, FETAL growth retardation, FETAL development, MATERNAL nutrition, PLACENTA, AMINO acids
Abstract

Gestational diabetes mellitus (GDM) is the most frequent pathophysiological state of pregnancy, which in many cases produces fetuses with macrosomia, requiring increased nutrient transport in the placenta. Recent studies by our group have demonstrated that leptin is a key hormone in placental physiology, and its expression is increased in placentas affected by GDM. However, the effect of leptin on placental nutrient transport, such as transport of glucose, amino acids, and lipids, is not fully understood. Thus, we aimed to review literature on the leptin effect involved in placental nutrient transport as well as activated leptin signaling pathways involved in the expression of placental transporters, which may contribute to an increase in placental nutrient transport in human pregnancies complicated by GDM. Leptin appears to be a relevant key hormone that regulates placental transport, and this regulation is altered in pathophysiological conditions such as gestational diabetes. Adaptations in the placental capacity to transport glucose, amino acids, and lipids may underlie both under- or overgrowth of the fetus when maternal nutrient and hormone levels are altered due to changes in maternal nutrition or metabolic disease. Implementing new strategies to modulate placental transport may improve maternal health and prove effective in normalizing fetal growth in cases of intrauterine growth restriction and fetal overgrowth. However, further studies are needed to confirm this hypothesis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles: ¿Qué parámetros debe incluir un perfil lipídico básico?Consensus document for lipid profile...

Author

Arrobas Velilla, Teresa, Guijarro, Carlos, Campuzano Ruiz, Raquel, Rodríguez Piñero, Manuel, Valderrama Marcos, José Francisco, Pérez Pérez, Antonio, Botana López, Manuel Antonio, Morais López, Ana, García Donaire, José Antonio, Carlos Obaya, Juan, Castilla Guerra, Luis, Pallares Carratalá, Vicente, Egocheaga Cabello, Isabel, Salgueira Lazo, Mercedes, Castellanos Rodrigo, María Mar, Mostaza Prieto, José María, Gómez Doblas, Juan José, and Buño Soto, Antonio

Abstract

Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results